Research Article

The Influence of Obesity on Work Ability, Respiratory Symptoms and Lung Function in Adults with Asthma

Geir Klepaker^{1,2*}, Martin Veel Svendsen¹, Jens Kristoffer Hertel³, Øystein Lunde Holla⁴, Paul Keefer Henneberger⁵,
Johnny Kongerud^{2,6} and Anne Kristin Møller Fell¹

¹ Department of Occupational and Environmental Medicine, Telemark Hospital, Skien, Norway.

² Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

³ Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway

⁴ Section of Medical Genetics, Department of Laboratory Medicine, Telemark Hospital, Skien, Norway.

⁵ Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia, United States of America

⁶ Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway

Short Title: The Influence of Obesity on Asthma in Adults

*Corresponding Author

Geir Klepaker

Department of Occupational and Environmental Medicine

Telemark Hospital Trust

Ulefossvegen 55

3710 Skien, Norway

[Tel: +47 35 00 31 54](tel:+4735003154)

Fax: +47 35 00 31 05

E-mail: geir.klepaker@sthf.no

Keywords: Asthma, Obesity, Lung function, Respiratory symptoms, Work ability.

Abstract

Background: Asthma is defined by variable respiratory symptoms and lung function, and may influence work ability. Similarly, obesity may contribute to respiratory symptoms, affect lung function and reduce work ability. Thus, assessment of the influence of obesity on work ability, respiratory symptoms and lung function in adults with asthma is needed. **Objectives:** We hypothesized that patients with obesity and asthma have more respiratory symptoms and reduced work ability and lung function compared with normal-weight patients with asthma. **Methods:** We examined 626 participants with physician-diagnosed asthma aged 18–52 years, recruited from a cross-sectional general population study, using a comprehensive questionnaire including work ability score, Asthma Control Test (ACT), height and weight, and spirometry with reversibility testing. **Results:** Participants with a body mass index (BMI) ≥ 30 kg/m² (i.e., obese) had a higher symptom score (odds ratio 1.78, 95% confidence interval 1.14–2.80), current use of asthma medication (1.60, 1.05–2.46) and incidence of ACT scores ≤ 19 (poor control), (1.81, 1.03–3.18) than participants with BMI ≤ 24.9 kg/m² (i.e. normal weight). Post-bronchodilator forced vital capacity as a percentage of predicted (FVC %) (β -coefficient –4.5) and pre-bronchodilator forced expiratory volume in one second as a percentage of predicted (FEV1%) (β -coefficient –4.6) were associated with BMI ≥ 30 kg/m². We found no statistically significant association of BMI > 30 kg/m² (compared to BMI < 24.9 kg/m²) with sick leave (1.21, 0.75–1.70) or reduced work ability (1.23, 0.74–2.04). **Conclusions:** There were indications that patients with obesity had a higher symptom burden, poorer asthma control, higher consumption of asthma medication and reduced lung function, in particular for FVC, compared with normal-weight patients.

Introduction

Both asthma and obesity are common globally and the prevalence of both diseases, particularly obesity, is rising. It is estimated that 339 million people and 650 million adults have asthma and obesity, respectively [1, 2]. Previous studies have recognized the combination of asthma and obesity as a distinct phenotype [3-5]. Subjects with this phenotype are difficult to treat, and are likely to be female, have asthma onset in mid-life, report more respiratory symptoms, and have reduced lung function measured by spirometry [3, 4].

Obesity can affect lung function and cause respiratory symptoms through several mechanisms, one of which is increased intra-abdominal pressure [6]. Increased weight also represents an increased workload contributing to respiratory symptoms such as dyspnoea on exertion [6]. The combination of obesity and asthma results in more respiratory symptoms and reduced lung function compared with either condition alone.

Several studies have reported an association between asthma severity and body mass index (BMI). One such study by Taylor and co-workers [7] found that, compared with normal-weight patients with asthma, patients with asthma and obesity were more likely to use asthma medication, to have more respiratory symptoms and have more severe asthma as measured by the Global Initiative for Asthma (GINA) severity score. Similar results were obtained by Bildstrup and co-workers, who found that asthma severity measured by GINA score increased significantly with higher BMI [8]. However, the current recommendation for assessing asthma is to assess its control rather than its severity because this is regarded by many to be a better basis for treatment decisions [9-11]. Using the Asthma Control Test (ACT), Schatz and co-workers found that a higher BMI was an independent predictor of poor asthma control [12]. However, there are few studies of asthma control assessed using ACT in patients with asthma and obesity, so additional studies are needed.

Sick leave and self-evaluated work ability can be used to describe the functional level of patients with asthma and obesity. For patients with asthma, this functional level may depend on asthma control and severity, but also on the burden of symptoms and in lung function. Subjects with obesity without any other diseases may also have reduced work ability and increased sick leave because of difficulties caused by their weight. A previous cross-sectional study in Denmark by Andersen and co-workers demonstrated that reduced work ability score (WAS), assessed by one of the questions in the Work Ability Index (WAI), was associated with greater BMI regardless of the presence of asthma [13]. In a Swedish longitudinal study (20-year follow-up) reported in 2017, asthma was shown to affect work ability [14]. To our knowledge, WAI assessed by WAS has not been studied in patients with asthma and obesity.

We hypothesized that patients with asthma and obesity have more respiratory symptoms, reduced work ability and reduced asthma control and lung function compared with normal-weight patients with asthma. Therefore, we aimed to assess the occurrence of self-reported respiratory symptoms, work ability and lung function in patients with asthma stratified by BMI.

Materials and Methods

Study Population

The study population was a sample of 626 participants with physician-diagnosed asthma from the cross-sectional baseline of the Telemark study, a population-based study that started in 2013, and which has been described in detail elsewhere [15]. In brief, the Telemark study commenced with a random sample of 50,000 inhabitants living in Telemark County in Norway, aged 16–50 years, who received a postal questionnaire. Of these, 48,142 were eligible and 16,099 responded (response rate 33%) [16]. Among the 16,099 respondents, 1857 (11.5%), reported having physician-diagnosed asthma. For the present study, all 1857 subjects were invited to attend a medical examination in 2014–2015; 651 of these (response rate 35%) completed further medical examinations, of whom 24

(4%) were not confirmed to have physician-diagnosed asthma and one of whom was excluded because of missing BMI data, leaving a total 626. The subjects were first sent an open invitation by mail with contact information and invited to make an appointment for a medical examination. In total, N=265 (42%) made an appointment and attended the examination. All those who did not make contact were given a specific time and date for the examination in a new letter resulting in N=361 (58%) included participants. Among the 1206 non-responders, 174 (14%) declined to attend, 210 (17%) had moved since address information was collected in 2013 and could not be reached, and three were excluded because of language problems. The remaining 819 (68%) simply did not attend their offered appointments.

Questionnaire

Before the medical examination, all participants completed a questionnaire that inquired about their occupational history and exposures, respiratory symptoms, allergies, comorbidities and possible confounders. The questionnaire was based on the European Community Respiratory Health Survey questionnaire and a survey instrument from a similar study from western Sweden [17]. All missing data regarding symptoms were recoded as the absence of that symptom. Age and sex were checked for accuracy against the Norwegian inhabitant registry. All subjects who had asthma symptoms during the past 12 months completed the ACT questionnaire and a score was calculated [18]. The ACT is a validated test for asthma control that consists of five questions [18]. All answers are given a score of 1–5, where five is the best, and the maximum score is 25. A total score <19 indicates poorly controlled asthma [18].

A score based on respiratory symptoms in the last 12 months was calculated for each individual by adding all positive answers to the questions Q1 to Q10 listed in Table 2, giving a maximum score of 10. The cut-off was set at ≥ 6 , which represented the upper tertile of the distribution of the symptom score.

Health-Related Outcomes

Anthropometric Measures

Height and weight were measured by trained study personnel using the same instruments and tools for all participants. As defined by the World Health Organization (WHO), BMI was measured in kg/m^2 . In the analyses, BMI was stratified into the following categories recommended by the WHO: normal weight $\leq 24.9 \text{ kg/m}^2$, overweight $25.0\text{--}29.9 \text{ kg/m}^2$ and obese $\geq 30 \text{ kg/m}^2$ [2]. Because some studies have used four BMI categories, also recommended by the WHO, we performed additional analyses stratified into the following categories: normal weight $\leq 24.9 \text{ kg/m}^2$, overweight $25.0\text{--}29.9 \text{ kg/m}^2$, obese $30.0\text{--}34.9 \text{ kg/m}^2$ and severely obese $\geq 35 \text{ kg/m}^2$.

Nitric oxide (FeNO) in exhaled air

FeNO was measured according to the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria [19] using the NIOX VERO (Aerocrine AB, Solna, Sweden). The FeNO measurements were performed before the lung function testing. FeNO was obtained from 558 (89%) subjects who managed one acceptable test one of three attempts.

Measurement of total IgE

Blood samples were obtained and total IgE analyzed by chemiluminescent immunoassay (Immulite2000 XPI, Siemens, Munich, Germany) in 621 (99%) subjects.

Lung Function Tests

Spirometry was performed in accordance with the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines [20] using a Jaeger Master Screen PFT (Erich Jaeger GmbH & Co. KG, Würzburg, Germany). All tests were performed under the guidance of one of three trained physicians. Forced vital capacity (FVC) as % of predicted, forced expiratory volume in one second (FEV_1) as % of predicted and FEV_1/FVC ratio were recorded. All tests were manually validated by two trained physicians (GK and JK) using flow–volume and time–volume curves according to ATS/ERS guidelines [20]. If a participant had no valid curves, their results were not included. All reference values were calculated using the equations from the Global Lung Function Initiative guidelines [21].

Reversibility testing: All participants with at least one acceptable spirometry test (n = 597, 95% of 626) were asked to inhale 0.4 mg salbutamol and spirometry was repeated after 10–15 minutes. An improvement in FEV₁ of at least 12% and >200 ml was defined as a positive result [22]. All tests were manually validated according to ATS/ERS guidelines, and tests without an acceptable curve were discarded. In total, 534 (85%) of the participants had an acceptable test. Reasons for not performing reversibility testing were refusal by the participant (n = 34, 5%), not having at least one acceptable spirometry curve (n = 13, 2%), contra-indications (e.g. severe cardio-vascular disease or pregnancy) (n = 7, 1%) and other reasons (n = 10, 1%).

Work Ability

Work ability was defined by the self-reported first question of the WAI questionnaire. This question is referred to as the WAS [23]. Briefly, the participants are asked to grade their work ability on a scale from 0 (I cannot work at all) to 10 (my employability is at its best right now). The WAS can be categorized into normal (score ≥8) and reduced (score <8) work ability [24]. Previous studies have demonstrated a strong association between WAS and the results of the complete WAI questionnaire [24, 25].

Sick Leave

Sick leave was defined as an affirmative answer to the question: ‘Have you been on sick leave over the course of the past 12 months?’. Analyses of sick leave were restricted to participants engaged in paid work within the previous 12 months.

Statistical Analyses

To analyse BMI results, we used Pearson’s chi-squared for categorical data and one-way analysis of variance (ANOVA) for continuous data, except for total IgE and FeNO when the Kruskal-Wallis test was used because of non-normal data distribution.

All dichotomous outcomes were analysed and adjusted for age, sex, smoking and education using multiple logistic regression. Continuous outcomes were analysed by linear regression and adjusted for the same confounders as the categorical outcomes. The symptom score was analysed by ANOVA and the dichotomized symptom score by logistic regression adjusted for age, sex, smoking and education.

All analyses were performed using the statistical package SPSS v23.0 (IBM SPSS Inc., Armonk, NY).

Results

The characteristics of the 626 participants with asthma stratified by BMI category are shown in Table 1. The majority of the participants were women ($n = 392$, 63%). Smoking status and level of education were similar across the categories. About half (52%) of all subjects had never smoked and 44% had completed a university education. Participants in the two highest BMI categories were older at examination and had a later onset of asthma symptoms than those in the lowest BMI category (Table 1). Values of FVC and FEV₁ before and after reversibility testing were both significantly lower among the participants in the highest BMI category than those in the lowest BMI category. However, there were no significant differences in the FEV₁/FVC ratio. The mean symptom score was 3.85 (SD 3.14) for all subjects and was significantly higher (4.45, SEM 0.25) among obese participants ($p = 0.004$). Median values of FeNO and total IgE were similar across the BMI categories.

Odds ratios (ORs) for the association of respiratory symptoms, control of asthma and work ability with BMI categories are presented in Table 2. After adjustment for age, sex, education and smoking, no specific respiratory symptom was associated with increased BMI. However, the risk of a symptom score ≥ 6 was significantly higher in the highest BMI category compared with the lowest (OR 1.78, 95% confidence interval [CI] 1.14–2.80). The highest BMI group also had an increased OR

for current use of asthma medication (OR 1.60, 95% CI 1.05–2.46) and a reduced ACT score (OR 1.81, 95% CI 1.03–3.18).

The outcome variables of symptom score, FEV₁% predicted, FVC% predicted and FEV₁/FVC ratio were analysed as continuous variables and adjusted for age, education, smoking status and sex, as shown in Table 3. The symptom score was significantly higher for participants with BMI ≥ 30 kg/m² (β -coefficient = 0.68, 95% CI 0.048–1.31). Both pre- and post-bronchodilator FVC were significantly negatively associated with BMI ≥ 30 kg/m², with β -coefficients of –6.5% and –4.5% respectively. The comparable decrements for FEV₁ were not as large, and only the pre-bronchodilator value differed significantly between groups. The β -coefficients for the FEV₁/FVC ratios were positive for both the middle and highest BMI categories in both the pre- and post-bronchodilator tests, consistent with the observation that the decrements were greater for FVC than for FEV₁.

Similar results were obtained when we stratified BMI into four categories (data not shown).

Discussion/Conclusion

The results of this study showed that participants with BMI ≥ 30 kg/m² had a significantly increased risk of a symptom score ≥ 6 compared with those with BMI ≤ 24.9 kg/m² (OR 1.78, 95% CI 1.14–2.80). The average symptom score was also significantly higher for participants in the highest BMI category ($p = 0.015$). When symptom scores were analysed using a linear regression model, we found similar results. To our knowledge, no previous studies have used a similar symptom score in subjects with asthma and obesity. The participants with BMI ≥ 30 kg/m² also had higher ORs for current use of asthma medication (OR 1.60, 95% CI 1.05–2.46) and reduced asthma control (OR 1.81, 95% CI 1.03–3.18) compared with subjects with BMI ≤ 24.9 kg/m².

In the regression models adjusted for covariates, no specific respiratory symptom had a significant association with increased BMI, although several did have ORs that were of borderline significance ($0.05 < p < 0.10$): Q2 ($p = 0.10$), Q5 ($p = 0.06$), Q6 ($p = 0.05$), and Q7 ($p = 0.10$). Other

studies have shown that some respiratory symptoms are more prevalent among patients with asthma and obesity, but the literature is contradictory. Kwon and co-workers examined 852 patients with asthma and found that wheezing within the previous 3 months had an OR of 3.2 ($p = 0.002$) in overweight subjects compared with normal-weight subjects, but that the incidence of cough and dyspnoea in the previous 3 months was not related to BMI [26]. Other studies have also found an association between obese asthma and wheezing [27, 28]. Bildstrup and co-workers demonstrated more severe cough and tightness in the chest with increased BMI in patients with asthma, whereas wheezing and shortness of breath were not related to BMI [8]. A possible interpretation of our results is that patients with asthma and obesity report the same respiratory symptoms as normal-weight asthma patients. A possible explanation for the conflicting results is a lack of statistical power and the small number of participants with sufficiently high BMI in our study because the effects may be related to extreme obesity. However, when we stratified BMI into four categories, we found comparable results, although the small number of subjects in the upper two categories (i.e. obese and severely obese) resulted in low statistical power (data not shown).

Control of asthma can be assessed by different questionnaires. One of the most frequently used is the ACT, but several similar tests are available. An advantage of the ACT is that it can be completed by patients and does not require any spirometry results or other medical tests. In the present study participants with $\text{BMI} \geq 30 \text{ kg/m}^2$ had a lower ACT score (OR 1.81, 95% CI 1.03–3.18), indicating that they had poorer asthma control than subjects with $\text{BMI} \leq 24.9 \text{ kg/m}^2$. Although Schatz and co-workers reported that a higher BMI was an independent predictor of poor asthma control [12], the proportion of individuals in their study with an ACT score < 20 was higher than that in our study. A possible explanation may be that Schatz and co-workers included subjects > 65 years of age, all of whom currently used asthma medication and had at least one asthma-related medical encounter within the previous two years. Pisi and co-workers studied a tertiary-care asthma outpatient population and reported an OR 1.6 (95% CI 1.04–2.55) for reduced ACT score among overweight

patients ($25 < \text{BMI} \leq 30 \text{ kg/m}^2$) compared with normal-weight patients ($18.5 \leq \text{BMI} \leq 25 \text{ kg/m}^2$) [29]. They did not analyse patients with higher BMIs. Because our study was population-based we expected our estimates to be lower than for a selective patient study, but the trend of reduced asthma control with increasing BMI seems to be consistent.

We wanted to use sick leave and self-evaluated work ability as a way to describe the functional level of patients with asthma and obesity. The reasons for a high frequency of sick leave and low work ability because of illness are complex and dependent on many different factors. For asthma, work ability may depend on asthma control and severity, but also on the burden of symptoms and lung function. After adjustment for age, sex, education and smoking, we found no increased sick leave or reduced WAS among subjects with asthma and overweight or obesity. When the analyses were performed using four BMI groups, we found an OR 2.0 (95% CI 0.99–4.0) for reduced WAS and OR 1.2 (95% CI 0.56–2.54) for sick leave when BMI was $\geq 35 \text{ kg/m}^2$. However, when we used four BMI categories the small number of subjects in the top two strata resulted in low statistical power.

Previous studies have shown an effect of BMI on sick leave, regardless of concurrent asthma. In a review by Neovius and co-workers, obesity was associated with a higher frequency and longer duration of sick leave [30]. The associations with overweight were less clear. Another review that included only longitudinal studies came to similar conclusions [31]. Similarly, several studies have reported more sick leave among patients with asthma, regardless of their weight, than healthy controls [32, 33]. To our knowledge, only one study has reported a higher level of sick leave among patients with asthma and obesity [34]. This Swedish study found that obesity was more common in subjects who were on sick leave because of respiratory problems than in the general population. However, the study included only a relatively small sample ($n = 237$) of patients on sick leave for longer than two weeks who were recruited from a compulsory insurance registry.

To our knowledge, the work ability measured as WAS in patients with asthma and obesity has not been studied previously. Work ability among subjects with increased BMI was assessed in a

previous cross-sectional study by Andersen and co-workers, which demonstrated a reduced work ability with increasing BMI [13], with an OR 1.69 (95% CI 1.10–2.62) for lower work ability among working subjects with grade III obesity ($\text{BMI} \geq 40 \text{ kg/m}^2$). In a longitudinal study (20-year follow-up) that did not consider obesity, asthma was shown to affect the WAI of participants, and the effect was increased by the asthma severity [14]. These studies indicate separate effects of asthma and obesity on work ability and sick leave. In many of the previous studies of work ability in subjects with obesity, the average BMI of participants has been considerably higher than the highest category in our study. Moreover, our study was a general population-based study of relatively young subjects, which may have affected our results. If these effects of obesity occur at higher BMI than that of most of our subjects, we lacked the statistical power to replicate such results.

We found a significant negative effect of BMI on FVC and FEV_1 . After reversibility testing with 0.4 mg salbutamol, the effect of obesity on FEV_1 in participants with asthma was no longer significant. After reversibility testing, the FEV_1/FVC ratio in the obese participants improved ($\beta = 1.7$, 95% CI 0.12–3.4), because the increase in FEV_1 exceeded the increase in FVC, consistent with the observation that the decrement in FEV_1 was less than the decrement in FVC. Studies of lung function in patients with asthma have shown that they have reduced FEV_1 and FEV_1/FVC ratio, indicating airway obstruction [35]. The effect of obesity on lung function is also well documented [36–39]. Both FEV_1 and FVC can be affected [36], but because the FEV_1/FVC ratio is often preserved, spirometry demonstrates a restrictive pattern in obese patients [38]. Several studies have shown an effect on spirometry in patients with asthma and overweight/obesity [29, 40, 41], but there are also studies that show no such effect [8]. In another study, obese adults without asthma had a lower FEV_1 , residual volume and total lung capacity than normal-weight subjects with asthma, suggesting that obesity may have stronger effects on FEV_1 and FVC in subjects without asthma than in those with asthma. Consistent with this, individuals with obesity have been reported to have lower FEV_1 and FVC than overweight individuals [39].

Strengths and Limitations

An important limitation of our study is that most outcomes were self-reported. However, we have used validated questionnaires that have also been used in other large epidemiological studies of respiratory health [17]. Although validated questionnaires can reduce information bias, such bias may still be important and reduce or inflate the associations of symptoms with exposure. Although most epidemiological studies are susceptible to bias because of selection and non-response, analyses of non-responders in our baseline study indicated that the frequencies of respiratory symptoms were similar in participants and non-participants [16]. To reduce selection bias, all eligible participants were invited for further medical examinations. We had a relative low response rate among those invited, which may introduce selection bias and could be considered as a limitation of the present study. We have self-reported data from the cross-sectional baseline survey on BMI, sex, education, smoking habit, sick leave and WAS in both responders and non-responders. A forward conditional logistic regression to test whether attendance to the medical examination was associated with BMI, sex, education, smoking habits, sick leave and work ability score (WAS) revealed statistically significant results only for somewhat older age (30-39 years: OR 2.2 (1.6-3.1); 40-50 years: OR (3.5 (2.7-4.7)) and current smoking (OR 0.67 (0.50-0.89)). While more robust participation by somewhat older individuals and reduced participation by current smokers may alter prevalence estimates, it is unlikely to bias the associations examined in this study. Such bias cannot, however, be ruled out entirely. To further decrease the likelihood of biased results all analyses in this paper are adjusted for age, smoking, sex and education.

Approximately 30% of the participants had a BMI ≥ 30 kg/m², a seemingly high proportion that may be an overestimation relative to the source population. In a survey conducted by the Norwegian National statistics agency in 2015, the proportion of obese inhabitants in the south eastern region of Norway (which includes Telemark county) in the age groups 25-44 and 45-64 was 15% and 18%, respectively [42]. Those data were self-reported, while ours were objectively

measured. For all 16 099 participants in the baseline study 15% reported obesity, while 20% reported obesity among the subjects with asthma. Furthermore, 21% of the individuals with asthma who attended the medical examination reported obesity in the baseline survey while 27% were measured to be obese when attending the medical examination, suggesting an underestimation of obesity in the self-reported data, a pattern that has also been observed by other investigators[43]. Based on these findings we therefore assume that this proportion of obesity is in accordance with the prevalence of obesity in south eastern Norway.

In our analyses, participants were defined by self-report of physician-diagnosed asthma. With our study design, we were not able to verify the diagnosis of asthma. However, a review by Torén and co-workers demonstrated that self-reported physician-diagnosed asthma has high specificity and gives a valid estimate [44]. Using this approach also allows the inclusion of participants who have had childhood asthma without recent symptoms, which may lower the frequency of positive responses among the participants. To assess this, we performed an additional analysis restricted to participants with active asthma, defined as having any respiratory symptoms during the previous 12 months. The analysis produced results comparable to those of the full analysis.

Another limitation of the study is using only BMI as a measure of obesity. Although BMI is widely used, it may not necessarily be the best measure of obesity. According to the WHO, BMI can be classified into six categories [45]. Even though our study cohort was of reasonable size ($n = 626$), the groups, particularly those in the extreme categories, became too small when we used these six categories as defined by the WHO. Larger studies or study designs other than population based may be needed to assess the effect of obesity classes II ($35\text{--}39.9 \text{ kg/m}^2$) and III ($>40 \text{ kg/m}^2$).

Because both asthma and obesity can individually contribute to respiratory symptoms and effects, we cannot determine the degree to which the associations we found were related to obesity and asthma. To our knowledge, few studies of the interaction of asthma and obesity have been conducted.

In conclusion, we found no clear evidence that any specific respiratory symptom was related to obese asthma. However, we did find indications of a higher symptom burden, reduced asthma control and higher consumption of asthma medication in participants with asthma and obesity than in patients with asthma and normal-weight. Obesity was found to be associated with reduced spirometry results, in particular for FVC. Although subjects with asthma and obesity had a higher respiratory symptom burden, poorer asthma control and reduced lung function compared with subjects with asthma and normal-weight, the work ability and sick leave seemed to be similar for both groups. Because of the small number of participants in our study with BMI ≥ 35 kg/m², we recommend further studies on this subpopulation.

Statements

Acknowledgements

We wish to thank Gølin Finckenhagen Gundersen and Regine Abrahamsen for participating in data collection and preparation.

Statement of Ethics

This study was conducted with the approval of The Regional Committee for Medical and Health Research Ethics in Norway (REC 2012/1665). All study participants provided informed written consent.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

Disclosure Statement

The authors have no conflicts of interest to declare.

Funding Sources

The work was supported by funding from Telemark Hospital Trust, Norway.

Author Contributions

GK drafted the paper and was involved in study design, data collection, data analyses and data interpretation. MVS was involved in study design, data collection, data management, data analyses and critical revision of the manuscript. JKH and ØLH were involved in data interpretation and critical revision of the manuscript. PKH, JK and AKMF were involved in study design, data analyses, data interpretation and critical revision of the manuscript. All authors approved the final manuscript.

References

- 1 The Global Asthma Report 2018, Global Asthma Network,
- 2 World Health Organisation Fact Sheets; Obesity and overweight, 2017,
- 3 Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R, Jr., Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *American journal of respiratory and critical care medicine* 2010;181:315-323.
- 4 Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH: Cluster analysis and clinical asthma phenotypes. *American journal of respiratory and critical care medicine* 2008;178:218-224.
- 5 Wenzel SE: Asthma phenotypes: the evolution from clinical to molecular approaches. *Nature medicine* 2012;18:716-725.
- 6 Zammit C, Liddicoat H, Moonsie I, Makker H: Obesity and respiratory diseases. *International journal of general medicine* 2010;3:335-343.
- 7 Taylor B, Mannino D, Brown C, Crocker D, Twum-Baah N, Holguin F: Body mass index and asthma severity in the National Asthma Survey. *Thorax* 2008;63:14-20.
- 8 Bildstrup L, Backer V, Thomsen SF: Increased body mass index predicts severity of asthma symptoms but not objective asthma traits in a large sample of asthmatics. *Journal of asthma* 2015;52:687-692.
- 9 Cockcroft DW, Swystun VA: Asthma control versus asthma severity. *The Journal of allergy and clinical immunology* 1996;98:1016-1018.
- 10 Humbert M, Holgate S, Boulet LP, Bousquet J: Asthma control or severity: that is the question. *Allergy* 2007;62:95-101.
- 11 Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szeffler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK: A new perspective on concepts of asthma severity and control. *The European respiratory journal* 2008;32:545-554.
- 12 Schatz M, Mosen DM, Kosinski M, Vollmer WM, Magid DJ, O'Connor E, Zeiger RS: Predictors of asthma control in a random sample of asthmatic patients. *The Journal of asthma* 2007;44:341-345.
- 13 Andersen LL, Izquierdo M, Sundstrup E: Overweight and obesity are progressively associated with lower work ability in the general working population: cross-sectional study among 10,000 adults. *International archives of occupational and environmental health* 2017;90:779-787.
- 14 Lindstrom I, Pallasaho P, Luukkonen R, Suojalehto H, Karjalainen J, Lauerma A, Karjalainen A: Reduced work ability in middle-aged men with asthma from youth--a 20-year follow-up. *Respiratory medicine* 2011;105:950-955.
- 15 Abrahamsen R, Fell AK, Svendsen MV, Andersson E, Toren K, Henneberger PK, Kongerud J: Association of respiratory symptoms and asthma with occupational exposures: findings from a population-based cross-sectional survey in Telemark, Norway. *BMJ open* 2017;7:e014018.
- 16 Abrahamsen R, Svendsen MV, Henneberger PK, Gundersen GF, Toren K, Kongerud J, Fell AK: Non-response in a cross-sectional study of respiratory health in Norway. *BMJ open* 2016;6:e009912.
- 17 Toren K, Ekerljung L, Kim JL, Hillstrom J, Wennergren G, Ronmark E, Lotvall J, Lundback B: Adult-onset asthma in west Sweden--incidence, sex differences and impact of occupational exposures. *Respiratory medicine* 2011;105:1622-1628.
- 18 Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB: Development of the asthma control test: a survey for assessing asthma control. *The Journal of allergy and clinical immunology* 2004;113:59-65.

- 19 ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *American journal of respiratory and critical care medicine* 2005;171:912-930.
- 20 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. *The European respiratory journal* 2005;26:319-338.
- 21 Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J: Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *The European respiratory journal* 2012;40:1324-1343.
- 22 Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. *The European respiratory journal* 2005;26:948-968.
- 23 Gould R IJ, Järvisalo J, Koskinen S. : Dimensions of work ability. Results from the 2000 survey. : Helsinki 2008, Finnish Centre for Pensions, 2008,
- 24 Ahlstrom L, Grimby-Ekman A, Hagberg M, Dellve L: The work ability index and single-item question: associations with sick leave, symptoms, and health--a prospective study of women on long-term sick leave. *Scandinavian journal of work, environment & health* 2010;36:404-412.
- 25 El Fassi M, Bocquet V, Majery N, Lair ML, Couffignal S, Mairiaux P: Work ability assessment in a worker population: comparison and determinants of Work Ability Index and Work Ability score. *BMC public health* 2013;13:305.
- 26 Kwon JW, Kim SH, Kim TB, Kim SH, Park HW, Chang YS, Jang AS, Cho YS, Nahm DH, Park JW, Yoon HJ, Cho YJ, Choi BW, Moon HB, Cho SH: Airway hyperresponsiveness is negatively associated with obesity or overweight status in patients with asthma. *International archives of allergy and immunology* 2012;159:187-193.
- 27 Schachter LM, Salome CM, Peat JK, Woolcock AJ: Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. *Thorax* 2001;56:4-8.
- 28 Kasteleyn MJ, Bonten TN, de Mutsert R, Thijs W, Hiemstra PS, le Cessie S, Rosendaal FR, Chavannes NH, Taube C: Pulmonary function, exhaled nitric oxide and symptoms in asthma patients with obesity: a cross-sectional study. *Respiratory research* 2017;18:205.
- 29 Pisi R, Aiello M, Tzani P, Marangio E, Olivieri D, Pisi G, Chetta A: Overweight is associated with airflow obstruction and poor disease control but not with exhaled nitric oxide change in an asthmatic population. *Respiration; international review of thoracic diseases* 2012;84:416-422.
- 30 Neovius K, Johansson K, Kark M, Neovius M: Obesity status and sick leave: a systematic review. *Obesity reviews : an official journal of the International Association for the Study of Obesity* 2009;10:17-27.
- 31 van Duijvenbode DC, Hoozemans MJ, van Poppel MN, Proper KI: The relationship between overweight and obesity, and sick leave: a systematic review. *International journal of obesity (2005)* 2009;33:807-816.
- 32 Hansen CL, Baelum J, Skadhauge L, Thomsen G, Omland O, Thilsing T, Dahl S, Sigsgaard T, Sherson D: Consequences of asthma on job absenteeism and job retention. *Scandinavian journal of public health* 2012;40:377-384.
- 33 Kauppi P, Salo P, Hakola R, Pentti J, Oksanen T, Kivimäki M, Vahtera J, Haahtela T: Allergic rhinitis alone or with asthma is associated with an increased risk of sickness absences. *Respiratory medicine* 2010;104:1654-1658.
- 34 Nathell L, Jensen I, Larsson K: High prevalence of obesity in asthmatic patients on sick leave. *Respiratory medicine* 2002;96:642-650.
- 35 Guerra S, Martinez FD: Epidemiology of the origins of airflow limitation in asthma. *Proceedings of the American Thoracic Society* 2009;6:707-711.

- 36 Melo LC, Silva MA, Calles AC: Obesity and lung function: a systematic review. *Einstein (Sao Paulo, Brazil)* 2014;12:120-125.
- 37 Littleton SW: Impact of obesity on respiratory function. *Respirology (Carlton, Vic)* 2012;17:43-49.
- 38 Mafort TT, Rufino R, Costa CH, Lopes AJ: Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. *Multidisciplinary respiratory medicine* 2016;11:28.
- 39 Forno E, Han YY, Mullen J, Celedon JC: Overweight, Obesity, and Lung Function in Children and Adults-A Meta-analysis. *The journal of allergy and clinical immunology In practice* 2018;6:570-581.e510.
- 40 Ciprandi G, Schiavetti I, Bellezza Fontana R, Sorbello V, Ricciardolo FL: Overweight and obesity as risk factors for impaired lung function in patients with asthma: A real-life experience. *Allergy and asthma proceedings* 2014;35:e62-71.
- 41 Gibeon D, Batuwita K, Osmond M, Heaney LG, Brightling CE, Niven R, Mansur A, Chaudhuri R, Bucknall CE, Rowe A, Guo Y, Bhavsar PK, Chung KF, Menzies-Gow A: Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. *Chest* 2013;143:406-414.
- 42 Statistics Norway, 2019, June 6, 2019,
- 43 Maukonen M, Mannisto S, Tolonen H: A comparison of measured versus self-reported anthropometrics for assessing obesity in adults: a literature review. *Scandinavian journal of public health* 2018;46:565-579.
- 44 Toren K, Brisman J, Jarvholm B: Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. *Chest* 1993;104:600-608.
- 45 World Health Organization- Regional Office for Europe. *Body Mass Index - BMI*, 2018,